1 l but one patient received variable doses of hepatitis B immune globulin.

2 s treated with entecavir monotherapy without hepatitis B immune globulin.

3 (100 mg daily) without the adjunctive use of hepatitis B immune globulin.

4 benefits of screening, including benefits of hepatitis B immune globulin and hepatitis B vaccine prop

5                              The efficacy of hepatitis B immune globulin and lamivudine to prevent de

6                               In addition to hepatitis B immune globulin and vaccination, oral antivi

7  use of oral antiviral therapy alone without hepatitis B immune globulin for chronic hepatitis B pati

8 cipients who were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily

9 bination of long-term antiviral and low-dose hepatitis B Immune globulin (HBIG) can effectively preve

10                                              Hepatitis B immune globulin (HBIG) dosing regimens have

11                                              Hepatitis B immune globulin (HBIG) has been an integral

12                                    Long-term hepatitis B immune globulin (HBIG) has been shown to red

13 routine use of antiviral therapy with either hepatitis B immune globulin (HBIg) or lamivudine; howeve

14 eratively, he received high-dose intravenous hepatitis B immune globulin (HBIG) treatment with contin

15 phylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG).

16 prophylaxis with hepatitis B vaccination and hepatitis B immune globulin in certain endemic regions a

17         Oral antiviral therapy alone without hepatitis B immune globulin is highly effective in preve